Multipl miyelomlu türk hastalarda EORTC QLQ kullanılarak hayat kalitesi değerlendirilmesi
Yükleniyor...
Dosyalar
Tarih
2011
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Trakya Üniversitesi Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmada, multipl miyelom hastalarında hastalığın kendisinden ve uygulanan çeşitli tedavilerden dolayı gözlenen depresyon, anksiyete ve hayat kalitesindeki değişiklikleri değerlendirilmeyi, bu değişikliklerin hastaların kişisel ve demografik özellikleri, hastalığın tipi ve evresi gibi özellikler ile ilişkisini belirlemeyi amaçladık. Ağustos 2010 - Şubat 2011 tarihleri arasında gerçekleştirilen çalışmaya, Trakya Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı Hematoloji Bilim Dalı'nca takip edilen multipl miyelom tanılı 50 hasta alındı. Değerlendirmeye alınan hastaların yaş, cins, hastalık süreleri, hastalık tipi ve evreleri, ilaç kullanımları, hastalıkları ile ilgili diğer bilgiler ve primer hastalık dışındaki bilgiler hastalardan direkt sözel bilgiyle ve dosyalarından edinildi. Hastalar, Salmon-Durie evreleme sistemi ve uluslararası evreleme sistemine göre evrelendirildi. Hastaların performans durumu "Eastern Cooperative Oncology Group" performans skalası ve Karnofsky performans skalası kullanılarak değerlendirildi. Çalışmaya alınan tüm hastalara Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-C30, Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-miyelom modülü 20, genel sağlık anketi ve hastane anksiyete ve depresyon ölçeği uygulandı. Uluslararası evreleme sistemine göre erken ve ileri evre olarak kabul edilen hastalar arasında Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-C30'un hem fonksiyonel hem de semptom skalaları skorları, genel hayat kalitesi skoru ve Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-miyelom modülü 20 sorgulama skorları açısından anlamlı fark saptanmadı (p>0,05). "Eastern Cooperative Oncology Group" performans durumuna göre iyi ve kötü performansı olan hastalar arasında Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-C30'un hem fonksiyonel (p<0,005) hem de semptom skalaları skorları (p<0,01), genel hayat kalitesi skoru (p<0,001) ve Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-miyelom modülü 20 sorgulama skorları (p?0,001) açısından anlamlı fark saptandı. Anksiyete varlığına veya yokluğuna göre hastalar karşılaştırıldığında Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-C30 fonksiyonel skala skorları (p<0,05) ve genel hayat kalitesi skorunda (p=0,005) iki grup arasında anlamlı fark saptanırken EORTC QLQ-MY20 sorgulama skorlarında (p>0,05) anlamlı fark saptanmadı. Depresyon varlığına veya yokluğuna göre hastalar karşılaştırıldığında hem Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-C30 skorları (p<0,05) ve genel hayat kalitesi skoru (p<0,001) hem de Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-miyelom modülü 20 skorları (p<0,05) açısından anlamlı fark saptandı. Ayrıca depresyon varlığı, genel hayat kalitesini olumsuz etkileyen bağımsız bir faktör olarak saptandı. Anahtar kelimeler: Multipl miyelom, hayat kalitesi, Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-C30, Avrupa Kanser Araştırma ve Tedavi Organizasyonu hayat kalitesi anketi-miyelom modülü 20.
Abstract
n this study, we aimed to evaluate depression, anxiety and changes of quality of life due to disease itself and treatments in patients with multiple myeloma and to determine the association between these disorders and features such as personal and demographic characteristics, type and stage of the disease. Fifty patients with the diagnosis of Multiple Myeloma followed up by the Division of Hematology of the Department of Internal Medicine, Trakya University Faculty of Medicine were enrolled in this study. Age, gender, duration of disease, type and stage of disease, drug usage, other informations related to disease and informations except primary disease belong to patients were obtained from patients' verbal informations as well as from medical records. Patients' performance status were determined by using "Eastern Cooperative Oncology Group" performance scale and Karnofsky's performance scale. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20, general health questionnaire and hospital anxiety and depression scale were performed to all patients in the study. No difference was observed between patients with early or advanced stage disease regarding the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 functional and symptom scale scores, global quality of life and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20 scores (p>0,05). However, significant difference was observed between patients with good or poor performance according to Eastern Cooperative Oncology Group performance scale regarding the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - C30 functional scale scores (p<0,005), symptom scale scores (p<0,01), global quality of life score (p<0,001) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20 scores (p<0,001). In respect of anxiety, significant difference was found between patients with or without anxiety using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - C30 functional scale scores (p<0,05) and global quality of life scores (p=0,005) of two groups while the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20 scores were similar (p>0,05). We observed significant difference between patients with or witout depression regarding European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - C30 scores (p<0,05), global quality of life scores (p<0,001) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20 scores (0<0,05). Additionally, presence of depression was determined as a poor independent factor associated with global quality of life. Key words: Multiple myeloma, quality of life, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20.
Abstract
n this study, we aimed to evaluate depression, anxiety and changes of quality of life due to disease itself and treatments in patients with multiple myeloma and to determine the association between these disorders and features such as personal and demographic characteristics, type and stage of the disease. Fifty patients with the diagnosis of Multiple Myeloma followed up by the Division of Hematology of the Department of Internal Medicine, Trakya University Faculty of Medicine were enrolled in this study. Age, gender, duration of disease, type and stage of disease, drug usage, other informations related to disease and informations except primary disease belong to patients were obtained from patients' verbal informations as well as from medical records. Patients' performance status were determined by using "Eastern Cooperative Oncology Group" performance scale and Karnofsky's performance scale. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20, general health questionnaire and hospital anxiety and depression scale were performed to all patients in the study. No difference was observed between patients with early or advanced stage disease regarding the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 functional and symptom scale scores, global quality of life and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20 scores (p>0,05). However, significant difference was observed between patients with good or poor performance according to Eastern Cooperative Oncology Group performance scale regarding the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - C30 functional scale scores (p<0,005), symptom scale scores (p<0,01), global quality of life score (p<0,001) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20 scores (p<0,001). In respect of anxiety, significant difference was found between patients with or without anxiety using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - C30 functional scale scores (p<0,05) and global quality of life scores (p=0,005) of two groups while the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20 scores were similar (p>0,05). We observed significant difference between patients with or witout depression regarding European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - C30 scores (p<0,05), global quality of life scores (p<0,001) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20 scores (0<0,05). Additionally, presence of depression was determined as a poor independent factor associated with global quality of life. Key words: Multiple myeloma, quality of life, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20.
Açıklama
Tıpta Uzmanlık Tezi
Anahtar Kelimeler
Hematoloji, Hematology, Multipl Miyelom, Hayat Kalitesi, EORTC QLQ, Quality of Life, Multiple Myeloma
